Search bioRxiv⌕ Search

Biology subjects

Molina-Lopez, C.

Publications and source records attributed to Molina-Lopez, C..

2 recordsLinked to original sources
bioRxiv2022

Soluble P2X7 receptor is elevated in the plasma of COVID-19 patients and correlates with disease severity

Inflammation is a tightly coordinated response against bacterial and viral infections, triggered by the production of pro-inflammatory cytokines. SARS-CoV-2 infection induces COVID-19 disease, characterized by an inflammatory response mediated through the activation of the NLRP3 inflammasome, which results in the production of IL-1{beta} and IL-18 along with pyroptotic cell death. The NLRP3 inflammasome could be also triggered by sterile danger signals such as extracellular ATP triggering the purinergic P2X7 receptor. Severe inflammation in the lungs of SARS-CoV-2 infected individuals is associated with pneumonia, hypoxia and acute respiratory distress syndrome, these being the causes of death associated with COVID-19. Both the P2X7 receptor and NLRP3 have been considered as potential pharmacological targets for treating inflammation in COVID-19. However, there is no experimental evidence of the involvement of the P2X7 receptor during COVID-19 disease. In the present study we determined the concentration of different cytokines and the P2X7 receptor in the plasma of COVID-19 patients and found that along with the increase in IL-6, IL-18 and the IL-1 receptor antagonist in the plasma of COVID-19 patients, there was also an increase in the purinergic P2X7 receptor. Increase in COVID-19 severity and C-reactive protein concentration positively correlated with increased concentration of the P2X7 receptor in the plasma, but not with IL-18 cytokine. The P2X7 receptor was found in the supernatant of human peripheral blood mononuclear cells after inflammasome activation. Therefore, our data suggest that determining levels of the P2X7 receptor in the plasma could be a novel biomarker of COVID-19 severity.

immunology↗
bioRxiv2022

Ornithine Lipid Activates Both TLR4 and the non-canonical NLRP3 Inflammasome.

Myeloid cells recognise Gram-negative bacterial lipopolysaccharides (LPS). LPS recognition triggers inflammatory reactions through Toll-like receptor 4 (TLR4) and primes the cells for inflammasome activation. In phosphate-depleted environments, bacteria cannot produce LPS. Instead, they increase their synthesis of ornithine lipid (OL), which is constitutively present in some pathogenic Gram-negative and -positive bacteria but absent in commensals. OL is implicated in bacterial pathogenicity, but the mechanism is unclear. Using primary murine macrophages and human peripheral blood mononuclear cells, we identify OL as a partial TLR4 agonist and an NLRP3 inflammasome activator. For this, OL directly activates TLR4 and indirectly activates NLRP3 in a potassium-efflux-dependent manner. OL also upregulates the expression of NLRP3 and pro-IL-1{beta} and induces cytokine secretion in primed and unprimed cells. By contrast, in the presence of LPS, OL functions as a partial TLR4 antagonist; LPS-induced TLR4 activation and inflammasome priming are inhibited by OL, leading to reduced TNF and IL-1{beta} secretion. We thus suggest that in phosphate-depleted environments, OL replaces LPS bacterial immunogenicity while constitutively present OL may allow bacteria to escape immune surveillance.

immunology↗